CRS Regulatory Science Fellowship Opportunity Broad Call
LEARN MORE
Improving the Process of Therapeutic Development
Harvard, MIT, and the FDA have partnered to create a center focused on regulatory science, bringing together a range of scientific disciplines that are applied to assess the quality, safety and efficacy of medicinal products and inform regulatory decision-making throughout the lifecycle of a medicine. Working across academia, industry, and government institutions, the Center promotes regulatory science through research and education programs, uniting stakeholders under a common mission: promoting optimal patient health outcomes through biomedical innovation and the availability of safe and effective diagnostics and treatments.
Featured Publications
The Regulatory Science Fellowship Program
Our fellowship program is affiliated with the FDA and focuses on training the next generation of regulatory science researchers. Learn more about the research our fellows are conducting or explore opportunities and how to get involved in our program.
News, Events, & Updates
Regulatory Science Forum – “An Insider’s Perspective on Drug Regulation”
Dr. Frank S. David & Susan Stewart, JD, LL. M
October 3rd, 2023 | 12pm – 1:00 PM ET
Innovators in Therapeutics Speaker Series with Dr. Michael Rosenblatt
October 17th, 2023 | 12pm – 1:00 PM ET
Twitter @Harvardmit_CRS
Join us at the next #RegSci forum with guest speaker @xelamb to learn about high-quality #DiagnosticTests in #Oncology! Register Here: https://harvard.zoom.us/meeting/register/tJwufu-srzgsEtKfheZRQoCUzr_FKKbLMxAe#/registration
Latest in @JAMAInternalMed from investigators
@HarvardMIT_CRS work with @US_FDA examining postmarketing safety of endovascular aneurysm repair devices. #EVAR devices have been subject to longstanding safety concerns & FDA warnings🧵http://bit.ly/45ELOSl
@ftbourgeois
@Bos_CHIP
How well can we assess device safety and performance using real-world data?
Our analysis in @JAMAInternalMed in collaboration with @HarvardMIT_CRS and @US_FDA shows feasibility, but challenges due to lack of device identifiers